Docetaxel and Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Has Been Completely Removed By Surgery

DISEASE CHARACTERISTICS: Pathologically proven non-small cell lung cancer (NSCLC) Stage IA-IIIB disease Underwent prior complete surgical resection (R0) no more than 2 months ago Eligible for cisplatin-based adjuvant chemotherapy PATIENT CHARACTERISTICS: Karnofsky performance status ≥ 70% Absolute neutrophil count ≥ 1,500/mm^3 Hemoglobin ≥ 8.0 g/dL Platelet count ≥ 100,000/mm^3 Creatinine clearance > 55 mL/min Total bilirubin normal Alkaline phosphatase, AST, and ALT must meet 1 of the following criteria: Alkaline phosphatase (AP) normal AND AST and ALT ≤ 5 times upper limit of normal (ULN) AP ≤ 2.5 times ULN AND AST and ALT ≤ 1.5 times ULN AP ≤ 5 times ULN AND AST and ALT normal Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for 3 months after completion of study treatment No history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80 No peripheral neuropathy > grade 1 No hearing deficit at baseline, even if it does not require a hearing aid or intervention or interfere with activities of daily life (i.e., CTCAE grade 2 or higher) PRIOR CONCURRENT THERAPY: See Disease Characteristics No prior postoperative radiation therapy No prior chemotherapy for NSCLC No prior docetaxel or cisplatin No concurrent prophylactic filgrastim (G-CSF) or pegfilgrastim